Euroopa Liit - eesti - EMA (European Medicines Agency)

virbac s.a. - clomipramine hydrochloride - psühhoanaleptikumid - koerad - as an aid in the treatment of separation related disorders in dogs manifested by destruction and inappropriate elimination (defecation and urination) and only in combination with behavioural modification techniques.

Euroopa Liit - eesti - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutiidi - suhkurtõbi, tüüp 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. uuringu tulemused seoses kombinatsioonid, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud, vt punktid 4. 4, 4. 5 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - ebapiisav adh-i sündroom - diureetikumid, - täiskasvanud patsientidel, kellel esineb sobimatu antidiureetilise hormooni sekretsiooni sündroom ("siadh") põhjustatud hüponatreemia.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Euroopa Liit - eesti - EMA (European Medicines Agency)

almirall s.a - tildrakizumab - psoriaas - immunosuppressants, interleukiin inhibiitorid, - ilumetri on näidustatud ravi täiskasvanute mõõduka kuni raske psoriaas, kes kandideerivad süsteemne ravi.

Eesti - eesti - Ravimiamet

orion corporation - mirtasapiin - suus dispergeeruv tablett - 15mg 90tk; 15mg 30tk

Eesti - eesti - Ravimiamet

sandoz pharmaceuticals d.d. - memantiin - suukaudne lahus - 10mg 1g 100ml 1tk; 10mg 1g 50ml 1tk

Eesti - eesti - Ravimiamet

medochemie limited - duloksetiin - gastroresistentne kõvakapsel - 30mg 30tk; 30mg 140tk; 30mg 100tk; 30mg 28tk; 30mg 196tk; 30mg 56tk; 30mg 98tk; 30mg 84tk

Eesti - eesti - Ravimiamet

krka d.d. novo mesto - mirtasapiin - suus dispergeeruv tablett - 15mg 70tk; 15mg 30tk; 15mg 96tk; 15mg 28tk; 15mg 14tk; 15mg 12tk; 15mg 18tk; 15mg 48tk; 15mg 6tk; 15mg 180tk; 15mg 20tk; 15mg 60tk; 15mg 90tk; 15mg 50tk